RUBICON RESEARCH LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 1,754 |
| EBITDA (ex other income) | 400 |
| margin % | 22.8 |
| Owners' profit | 247 |
| EPS, as reported (₹) | 15.52 |
| ROE % · ROCE % | 19.1 · 24.3 |
| Debt / equity (x) | 0.20 |
| Cash from operations | 205 |
| Capex | (229) |
| ₹ crore | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|
| Revenue | 412 | 476 | 514 | 534 |
| Profit before tax | 72 | 91 | 99 | 110 |
| Net profit | 54 | 73 | 77 | 85 |
| EPS (₹) | 3.49 | 4.46 | 4.66 | 5.13 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 29 Aug 2026 · Promoter General Atlantic sells 8.45% stake in Rubicon Research via open market | ownership changes | high | — | — |
| 27 Aug 2026 · General Atlantic sells 8.45% stake in Rubicon Research via open market | ownership changes | high | — | — |
| 26 Aug 2026 · 27th AGM: All 9 resolutions passed including dividend, ESOP 2026 and subsidiary merger | board shareholder meetings | low | — | — |
| 26 Aug 2026 · 27th AGM held; 9 resolutions tabled including dividend, ESOP 2026 and KIA merger | board shareholder meetings | low | — | — |
| 19 Aug 2026 · Rubicon Research Q1 FY27 transcript: PAT up 96%, EBITDA guidance raised to 23% | investor communications | medium | — | — |
| 14 Aug 2026 · Audio recording of Q1 FY27 earnings call now available on website | investor communications | low | — | — |
| 14 Aug 2026 · IPO fund-use deadline extended to March 2027; ₹830.67 million unutilised | compliance | minimal | — | — |
| 14 Aug 2026 · Rubicon Research announces CFO transition and Chairman term extension | management changes | high | — | — |
| 14 Aug 2026 · Rubicon Research Q1 FY27 results: revenue up 52%, PAT up 96% | investor communications | medium | — | — |
| 14 Aug 2026 · Rubicon Research Q1FY27 Investor Presentation: Revenue up 51.6% YoY | investor communications | medium | — | — |
| Where a broker report shows | This document shows |
|---|
| DR. REDDY S LABORATORIES |
| 97,319 |
| 30.1 |
| 2.55 |
| 13.1 |
| 10.9 |
| 13.0 |
| 12.1 |
| 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 103.7 | 28.9 | 157 of 169 | 7% |
| P/B | 23.6 | 3.3 | 161 of 163 | 1% |
| ROCE | 21.5 | 10.8 | 30 of 183 | 84% |
| ROE | 19.1 | 10.4 | 23 of 171 | 87% |
| Debt / Equity | 0.2 | 0.1 | 101 of 171 | 41% |
| EBITDA margin | 25.2 | 17.5 | 52 of 165 | 69% |
| Market cap | 30420 | 839 | 22 of 182 | 88% |
| Why |
|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
